This study is accepting new patients by invitation only

Long-Term Follow-up Study

a study on Lymphoma Non-Hodgkin Lymphoma Hematologic Malignancy Multiple Myeloma Acute Myeloid Leukemia Leukemia Hematologic Neoplasms

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at Irvine, California and other locations
Dates
study started
study ends around

Description

Summary

This is an observational, non-interventional, LTFS of investigational Caribou therapies in patients who have participated in a parent study: a prior Caribou-sponsored clinical study, special access program, or an IIT. The objective is to evaluate the long-term safety, through 15 years post infusion, in patients who received IPs in a Caribou-sponsored clinical study, special access program or IIT.

Official Title

An Observational Long-Term Follow-up Study of Patients Who Received Prior Caribou Cell Therapy

Details

This is an observational, non-interventional, LTFS of investigational Caribou therapies in patients who have participated in a parent study: a prior Caribou-sponsored clinical study, special access program, or an IIT. The objective is to evaluate the long-term safety, through 15 years post infusion, in patients who received IPs in a Caribou-sponsored clinical study, special access program or IIT.

Keywords

Lymphoma, Non-Hodgkin, Relapsed Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Lymphoma, B Cell Lymphoma, B-Cell Non-Hodgkin's Lymphoma, Hematologic Malignancy, Relapsed/Refractory Multiple Myeloma, Relapsed/Refractory Acute Myeloid Leukemia, Allogeneic CAR-T, CB-010, CB-011, CB-012, Multiple Myeloma, B-Cell Lymphoma, Hematologic Neoplasms, Caribou-sponsored investigational therapy

Eligibility

You can join if…

Open to people ages 18 years and up

  • Written informed consent (by patient or legal representative) obtained prior to study-specific activities/enrollment
  • Completed a Caribou-sponsored study or was administered Caribou IP under a special access program or as part of an IIT
  • Use of an effective method of birth control by women of childbearing potential and their partners and men with partners of childbearing potential (partners must also use an effective birth control method) through 12 months post IP infusion.

You CAN'T join if...

  • None

Locations

  • University of California Irvine
    Irvine California 92868 United States
  • University of California San Diego
    La Jolla California 92093 United States

Details

Status
accepting new patients by invitation only
Start Date
Completion Date
(estimated)
Sponsor
Caribou Biosciences, Inc.
ID
NCT05332054
Study Type
Observational
Participants
Expecting 150 study participants
Last Updated